10-QPeriod: Q3 FY2023

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q3 Ended Sep 30, 2023

Filed November 7, 2023For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a solid third quarter and first nine months of 2023, demonstrating continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Total product revenues reached $2.48 billion for the third quarter, an increase of 6% year-over-year, and $7.35 billion for the nine-month period, up 11%. Net income also saw a healthy increase, rising to $1.04 billion for the quarter and $2.65 billion for the nine months. The company is actively investing in its R&D pipeline, with significant increases in R&D and acquired in-process R&D expenses, reflecting progress in key therapeutic areas beyond CF, including sickle cell disease, beta-thalassemia, and various pain and kidney disease programs. Financially, Vertex maintains a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $13.6 billion as of September 30, 2023. The company also continues to execute its capital allocation strategy, evidenced by the $2.7 billion remaining authorization for share repurchases. Upcoming catalysts include regulatory decisions for exa-cel in sickle cell disease and beta-thalassemia, as well as anticipated results from pivotal clinical trials for vanzacaftor/tezacaftor/deutivacaftor in CF and VX-548 in acute pain, positioning the company for potential future growth.

Financial Highlights

48 data points
Beta

Revenue

$2.48B

87.2% Gross Margin

Net Income

$1.04B

41.7% Net Margin

EPS (Diluted)

$3.97

Total Assets

$21.73B

Cash & Equivalents

$11.11B

Free Cash Flow

$1.23B

Financial Statements
Beta
Revenue$2.48B
Cost of Revenue$318.70M
Gross Profit$2.16B
SG&A Expenses$263.80M
Operating Expenses$1.45B
Operating Income$1.04B
Net Income$1.04B
EPS (Basic)$4.01
EPS (Diluted)$3.97
Shares Outstanding (Basic)258.00M
Shares Outstanding (Diluted)260.60M

Key Highlights

  • 1Product revenues increased by 6% to $2.48 billion in Q3 2023 and by 11% to $7.35 billion for the first nine months of 2023, primarily driven by TRIKAFTA/KAFTRIO.
  • 2Net income grew to $1.04 billion in Q3 2023 (up 11% YoY) and $2.65 billion for the first nine months of 2023 (up 6% YoY).
  • 3Research and Development (R&D) expenses significantly increased by 26% in Q3 and 27% for the nine-month period, reflecting investments in pipeline advancement.
  • 4Acquired in-process R&D (AIPR&D) expenses surged by 78% in Q3 and 448% for the nine-month period, mainly due to significant upfront payments for collaborations and asset acquisitions.
  • 5The company ended the period with a robust cash, cash equivalents, and marketable securities balance of $13.6 billion, up 25% from year-end 2022.
  • 6Vertex is awaiting key regulatory decisions for exa-cel (SCD/TDT) with FDA action dates in December 2023 and March 2024.
  • 7Pivotal clinical trial results for vanzacaftor/tezacaftor/deutivacaftor (CF) and VX-548 (acute pain) are expected in early 2024.

Frequently Asked Questions

Revenue growth is primarily driven by the strong performance of TRIKAFTA/KAFTRIO, especially with its recent launch in younger children (ages 2-5) and continued uptake in ex-U.S. markets following reimbursement achievements and label expansions. This has led to a 6% increase in Q3 2023 revenue and an 11% increase for the first nine months of 2023.

Vertex is significantly increasing its investment in research and development (R&D) and acquired in-process R&D (AIPR&D). R&D expenses increased by 26% in Q3 and 27% for the nine months, while AIPR&D saw substantial growth due to strategic collaborations and asset acquisitions, such as those with Entrada Therapeutics and CRISPR Therapeutics. This indicates a strong focus on advancing its pipeline in areas beyond cystic fibrosis, including sickle cell disease, beta-thalassemia, and other serious diseases.

Vertex maintains a very strong financial position. Its cash, cash equivalents, and marketable securities increased by 25% to $13.6 billion as of September 30, 2023. This robust liquidity, combined with strong operating cash flows, provides ample resources to fund ongoing operations, R&D investments, and strategic initiatives.

Key upcoming catalysts include regulatory decisions for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta-thalassemia, with FDA action dates in December 2023 and March 2024. Additionally, investors can anticipate the results from pivotal clinical trials for vanzacaftor/tezacaftor/deutivacaftor in cystic fibrosis and VX-548 in acute pain, expected in early 2024.